The United States Food and Drug Administration (FDA) announced on Thursday (5) the limitation of the use of the Janssen (Johnson & Johnson) vaccine for Covid-19 in adults due to the risk of a rare syndrome. of blood clotting.
The vaccine is authorized for people over 18 and is one of three against Covid-19 released for use in the United States.
The agency said the Janssen injection may be given in cases where authorized or approved Covid-19 vaccines are not accessible or if an individual is less interested in using the other two injections.
The FDA stated that its analysis determined that the risk of thrombosis with thrombocytopenia syndrome following administration of the vaccine warrants limiting the authorization.
Johnson & Johnson did not immediately respond to a Reuters request for comment.
your subscription can be worth even more
Do you already know the advantages of being a Folha subscriber? In addition to having access to reports and columns, you have exclusive newsletters (find out here). You can also download our free app from the Apple Store or Google Play to receive alerts on the top news of the day. Your subscription helps us to make independent and quality journalism. Thank you!
your subscription is worth a lot
More than 180 reports and analyzes published each day. A team of more than 200 columnists and bloggers. A professional journalism that supervises the public power, conveys useful and inspiring news, counterpoints the intolerance of social networks and draws a clear line between truth and lie. How much does it cost to help produce this content?
SUBSCRIBE FOR 3 MONTHS FOR BRL 1.90
Chad-98Weaver, a distinguished author at NewsBulletin247, excels in the craft of article writing. With a keen eye for detail and a penchant for storytelling, Chad delivers informative and engaging content that resonates with readers across various subjects. His contributions are a testament to his dedication and expertise in the field of journalism.